Skip to main content
Clinical Trials/NCT06561386
NCT06561386
Recruiting
Phase 3

A Phase 3, Randomized, Open-label Study of Nivolumab + Relatlimab Fixed-dose Combination With Chemotherapy Versus Pembrolizumab With Chemotherapy as First-line Treatment for Participants With Non-squamous (NSQ), Stage IV or Recurrent Non-small Cell Lung Cancer and With Tumor Cell PD-L1 Expression ≥ 1%

Bristol-Myers Squibb523 sites in 5 countries1,000 target enrollmentOctober 7, 2024

Overview

Phase
Phase 3
Intervention
Nivolumab
Conditions
Non-small Cell Lung Cancer
Sponsor
Bristol-Myers Squibb
Enrollment
1000
Locations
523
Primary Endpoint
Overall survival (OS) in randomized participants with PD-L1 1% to 49%
Status
Recruiting
Last Updated
last month

Overview

Brief Summary

The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD-L1 expression ≥ 1%

Registry
clinicaltrials.gov
Start Date
October 7, 2024
End Date
August 4, 2032
Last Updated
last month
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Participants must have histologically confirmed Stage IV or recurrent Non-small Cell Lung Cancer (NSCLC) of non-squamous (NSQ) histology with no prior systemic anti-cancer therapy given as primary therapy for advanced or metastatic disease.
  • Participants must have measurable PD-L1 ≥ 1% Tumor Cell (TC) score by the investigational PD-L1 immunohistochemistry (IHC) assay VENTANA PD-L1 (SP263) CDx Assay conducted by central laboratory during the screening period prior to randomization.
  • Participants must have measurable disease by computed tomography (CT) or magnetic resonance imaging (MRI) per RECIST v1.1 criteria.
  • Participants must have an Easter Cooperative Oncology Group (ECOG) performance status of ≤ 1 at screening.
  • Participants must have a life expectancy of at least 3 months at the time of randomization.

Exclusion Criteria

  • Participants must not be pregnant and/or breastfeeding.
  • Participants with epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or ROS-1 mutations that are sensitive to available targeted inhibitor therapy. Participants with unknown EGFR, ALK, or ROS-1 status are excluded.
  • Participants with known BRAFV600E mutations, that are sensitive to available targeted inhibitor therapy; participants with known activating rearranged during transfection (RET) mutations or neurotrophic tyrosine receptor kinase (NTRK) fusion gene alterations are excluded. Participants with unknown or indeterminate BRAF mutation, activating RET mutations or NTRK fusion gene alterations are eligible.
  • Participants must not have untreated central nervous system (CNS) metastases.
  • Participants must not have leptomeningeal metastases (carcinomatous meningitis).
  • Participants must not have concurrent malignancy requiring treatment.
  • Participants must not have an active autoimmune disease.
  • Participants must not have history of interstitial lung disease or pneumonitis that required oral or intravenous (IV) glucocorticoids to assist with management.
  • Participants must not have a history of myocarditis.
  • Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, or anti-CTLA-4 antibody, or other antibody or drug targeting T-cell co-stimulation or checkpoint pathways.

Arms & Interventions

Arm A

Intervention: Nivolumab

Arm A

Intervention: Relatlimab

Arm A

Intervention: Carboplatin

Arm A

Intervention: Pemetrexed

Arm A

Intervention: Cisplatin

Arm B

Intervention: Pembrolizumab

Arm B

Intervention: Carboplatin

Arm B

Intervention: Pemetrexed

Arm B

Intervention: Cisplatin

Outcomes

Primary Outcomes

Overall survival (OS) in randomized participants with PD-L1 1% to 49%

Time Frame: Up to 5 years

Secondary Outcomes

  • OS in randomized participants with PD-L1 ≥ 1%(Up to 5 years)
  • Progression-free survival (PFS) as assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)(Up to 5 years)
  • Overall response rate (ORR)(Up to 5 years)
  • Duration of response (DoR)(Up to 5 years)
  • Number of participants with adverse events (AEs)(Up to 2.5 years)
  • Number of participants with serious adverse events (SAEs)(Up to 2.5 years)
  • Number of participants with immune-mediated adverse events (IMAEs)(Up to 2.5 years)
  • The time until definitive deterioration based on non-small cell lung cancer - symptom assessment questionnaire (NSCLC-SAQ) total score(Up to 2 years)

Study Sites (523)

Loading locations...

Similar Trials